TABLE 3.

Studies Examining Processing Speed

Reference	Population, N	Time Since Treatment	Treatment Regimen	Outcome	Limitations
Aukema et al. (2009)	6 medulloblastoma survivors; Cross-sectional	Median = 3.5 y since diagnosis	All had surgery, chemo + CRT	Medulloblastoma group scored worse on processing speed, had lower WMFA	Small sample size; No control group
Mabbott et al. (2008)	62 survivors of PF tumor; 10 non-CNS tumor control subjects; Cross-sectional	Mean since diagnosis: PF group = 5.4 y; non-CNS tumor group = 5.9 y	PF group: 31/62 received CRT; 31/62 received surgery only; Non-CNS group received chemo + surgery	PF-CRT group had lowest processing speed scores, followed by PF-surgery group. Non-CNS tumor group had best scores.	Heterogeneity in type of treatment received; Unequal group sizes.
Ribi et al. (2005)	18 medulloblastoma survivors; Cross-sectional	Mean age at diagnosis: 6.8 y; Mean age at assessment: 18.9 y	Surgery + CRT: 4/18; Surgery + Chemo: 12/18; Chemo only: 2/18	11/14 showed deficits in attention/processing speed factor	Heterogeneity in treatment; No control group; Small sample size.
Spiegler et al. (2004)	34 posterior fossa tumor survivors; Longitudinal	Range (0–10 y)	Surgery + CRT: 10/34; Surgery, CRT, + chemo: 24/34	Processing speed declined steadily after treatment.	Heterogeneity in treatment; No control group; Missing data.

Note. Y = years; chemo = chemotherapy; CRT = cranial radiation therapy; WMFA = white matter fractional anisotropy; PF = posterior fossa; CNS = central nervous system.